Cyclin E is overexpressed by clear cell carcinomas of the endometrium and is a prognostic indicator of survival

Objective: Upregulation of cyclin E and cyclin D1-6 accelerates the transition from G1 to S phase. The objective of this study was to determine if cyclin D1 and E are prognostic indicators in endometrial cancer. Materials and Methods: Surgically-treated patients with endometrial carcinoma had their tumors stained for nuclear expression of cyclin D1 and E. Quantification of staining and measurement of growth phase fraction were performed using image analysis. FIGO stage, grade, and histology were also analyzed. Results: Cyclin D1 and E expression was unrelated to DNA index (p = 0.93). While cyclin D1 expression did not correlate with S+G2M phase fraction (p = 0.69), increased cyclin E expression was directly correlated with increased S+G2M phase fraction (p = 0.002). Cyclin E expression was highest in clear cell carcinomas (p = 0.042) while cyclin D1 expression was highest in adenosquamous carcinomas (p = 0.028). Patients dying from cancer had significantly higher expression of cyclin D1 (p = 0.042) and E (p = 0.02) as compared to patients surviving their disease. Multivariate logistic regression revealed FIGO stage, grade, and lack of cyclin E overexpression to be independent prognostic indicators of survival. Conclusion: Cyclin E expression is related to increased growth fraction, clear cell histology, and decreased survival in patients with endometrial cancer.

Cyclin D; Cyclin E; Cell cycle; Clear cell carcinoma; Endometrial cancer.

[1] Rebecca Siegel R., Naishadham D., Jemal A.: “Cancer Statistics, 2012”. C.A. J. Clin., 2012, 62, 10.

[2] Liu F.S.: “Molecular carcinogenesis of endometrial cancer”. Taiwan J. Obstet. Gynecol., 2007, 46, 26.

[3] Olawaiye A.B., Boruta D.M. 2nd.: “Management of women with clear cell endometrial cancer: a Society of Gynecologic Oncology (SGO) review”. Gynecol. Oncol., 2009, 113, 277.

[4] Kawauchi S., Yamamoto Y., Uchida K., Chochi Y., Kondo T., Oga A., Sasaki K.: “Significance of cyclin E and p27 expression in malignant ovarian germ cell tumors: correlation with the cell proliferation activity and clinicopathologic features”. Oncol. Rep., 2006, 16, 1029.

[5] Geisler H.E., Geisler J.P., Miller G.A., Geisler M.J., Wiemann M.C., Zhou Z., Crabtree W.: “p21 and p53 in ovarian cancer: their combined staining is more valuable than either alone”. Cancer, 2001, 92, 781.

[6] Geisler J.P., Zhou Z., Miller G.A., Wiemann M.C., Geisler H.E.: “DNA index by image analysis in advanced endometrial carcinoma”. J. Surg. Oncol., 1996, 63, 91.

[7] Geisler J.P., Zhou Z., Miller G.A., Wiemann M.C., Geisler H.E.: “MIB-1: a predictor of survival in patients with ovarian carcinoma”. Int. J. Gynecol. Cancer, 1998, 8, 392.

[8] Zapiecki K.M., Manahan K.J., Geisler J.P.: “Using a Panel of Immunohistochemical Stains to Determine Risk of Lymph Node Metastases in Women with Endometrioid Adenocarcinoma of the Endometrium”. J. Cancer Ther., 2011, 2, 497.

[9] Geisler J.P., Wiemann M.C., Zhou Z., Miller G.A., Geisler H.E.: “Proliferation index determined by MIB-1 and recurrence in endometrial cancer”. Gynecol. Oncol., 1996, 61, 373.

[10] Yasmeen A., Berdel W.E., Serve H., Müller-Tidow C.: “E.- and Atype cyclins as markers for cancer diagnosis and prognosis”. Expert Rev. Mol. Diag., 2003, 3, 617.

[11] Spruck C.H., Won K.A., Reed S.I.: “Deregulated cyclin E induces chromosome instability”. Nature, 1999, 401, 297.

[12] Möröy T., Geisen C.: “Cyclin E”. Int. J. Biochem. Cell. Biol., 2004, 36, 1424.

[13] Geisler J.P., Wiemann M.C., Zhou Z., Miller G.A., Geisler H.E.: “DNA index by image analysis in advanced endometrial carcinoma”. J. Surg. Oncol., 1996, 63, 91.

[14] Kim J.K., Diehl J.A.: “Nuclear cyclin D1: an oncogenic driver in human cancer”. J. Cell. Physiol., 2009, 220, 292.

[15] Lambert L., Keyomarsi K.: “Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles’ heel?”. Adv. Exp. Med. Biol., 2007, 608, 52.

[16] Geisler J.P., Wiemann M.C., Zhou Z., Miller G.A., Geisler H.E.: “Proliferation index determined by MIB-1 and recurrence in endometrial cancer”. Gynecol. Oncol., 1996, 61, 373.

[17] Tashiro E., Tsuchiya A., Imoto M.: “Functions of cyclin D1 as an oncogene and regulation of cyclin D1 expression”. Cancer Sci., 2007, 98, 629.